postsurgical pain control

postsurgical pain control

agents (e.g. acemetacin, diclofenac, flurbiprofen, ibuprofen, ketoprofen, ketoralac) licensed for postoperative pain control; non-steroidal anti-inflammatory drugs alone do not usually achieve adequate postoperative pain control Table 1
Table 1: Principles of pain management
StepPain typeManagement regimeExamples of drug
1Mild to moderateNon-opioid analgesics:
Paracetamol
  • NSAIDs:

  • Pyrazoles


± Adjuvant drugs:
Paracetamol
Aspirin; ibuprofen pheylbutazone; dipyrone
Amitriptyline
Gabapentin
Mexilitine
Ketamine
2Moderate to severeLess potent opioidsCodeine
  • Dihydrocodeine

  • Dextropropoxyphene

± Non-opioid analgesics
± Adjuvant drugs
Paracetamol
As above
3SeverePotent opioidsMorphine
Tramadol
Fentanyl
Oxycodone
± Non-opioid analgesics
± Adjuvant drugs
Paracetamol
As above

Pain management should address both the nociceptive and neuropathic components of pain.

NSAIDs, non-steroidal anti-inflammatory drugs.

References in periodicals archive ?
Phase 4 clinical trial results for bupivacaine liposome injectable suspension as the foundation of a multimodal analgesic regimen versus a standard opioid-based regimen for postsurgical pain control were published in the January issue of Current Therapeutic Research.
The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL([R]) (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012.
The company's product pipeline includes postsurgical pain control drug EXPAREL, which was commercially launched in the United States last month, DepoCyt(e), for treatment of lymphomatous meningitis, and DepoDur, for postsurgical pain.
Pacira Pharmaceuticals is currently developing non-opioid products for postsurgical pain control.
Pacira Pharmaceuticals is currently focused on the development of non-opioid products for postsurgical pain control.
100 percent of the available subjects reported being either satisfied or extremely satisfied with their postsurgical pain control at hospital discharge, at 72 hours and on day 10.
The company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL[R] (bupivacaine liposome injectable suspension), was commercially launched in the United States in April 2012.
The company's current emphasis is the development of non-opioid products for postsurgical pain control, and three commercially available products have utilized the Pacira proprietary product delivery technology DepoFoam([R]), a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.